[SCHEDULE 13G/A] Travere Therapeutics, Inc. Amended Passive Investment Disclosure
Macquarie Reports 0% Stake in Travere Therapeutics
Travere Therapeutics Inc. received an amended Schedule 13G/A from Macquarie entities indicating they no longer hold a reportable stake in the company’s common shares.
Travere Therapeutics Inc. received an amended Schedule 13G/A from Macquarie entities indicating they no longer hold a reportable stake in the company’s common shares. Macquarie Group Limited, Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report beneficial ownership of 0 shares, or 0.00% of the class, as of 12/31/2025.
The filers state the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics.
Positive
None.
Negative
None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Macquarie’s Schedule 13G/A say about its TVTX ownership?
Macquarie’s amended Schedule 13G/A reports beneficial ownership of 0 common shares of Travere Therapeutics Inc., representing 0.00% of the class as of December 31, 2025. This indicates Macquarie no longer has a reportable equity stake under Section 13(d) rules.
Which Macquarie entities are reporting on Travere Therapeutics (TVTX)?
The filing is jointly made by Macquarie Group Limited, Macquarie Management Holdings Inc., and Macquarie Investment Management Business Trust. Each entity reports identical figures, with 0 shares beneficially owned and 0.00% of Travere Therapeutics’ common shares outstanding.
What percentage of Travere Therapeutics (TVTX) does Macquarie now own?
Macquarie reports beneficial ownership of 0.00% of Travere Therapeutics Inc.’s common shares. The Schedule 13G/A cover pages show 0 shares with no sole or shared voting or dispositive power, meaning no reportable equity position remains as of the stated date.
What class of Travere Therapeutics securities is covered in this 13G/A?
The Schedule 13G/A relates to common shares of Travere Therapeutics Inc., identified by CUSIP 89422G107. All reported ownership figures, including the 0-share balance and 0.00% percentage, apply specifically to this common equity class, not to any other securities or instruments.
What is the event date for Macquarie’s ownership report on TVTX?
The event that triggered this Schedule 13G/A is dated December 31, 2025. As of that date, Macquarie’s reporting entities disclose beneficial ownership of 0 shares of Travere Therapeutics common stock and no voting or dispositive power over any such securities.
How does the filing describe Macquarie’s intent regarding control of TVTX?
The certification states the securities referenced were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Travere Therapeutics. It also notes they are not held in connection with any control-related transaction, except for limited nomination activities.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Travere Therapeutics Inc
(Name of Issuer)
Common Shares
(Title of Class of Securities)
89422G107
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
89422G107
1
Names of Reporting Persons
Macquarie Group Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
AUSTRALIA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP No.
89422G107
1
Names of Reporting Persons
Macquarie Management Holdings Inc
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP No.
89422G107
1
Names of Reporting Persons
Macquarie Investment Management Business Trust
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Travere Therapeutics Inc
(b)
Address of issuer's principal executive offices:
3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
Item 2.
(a)
Name of person filing:
This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc, and Macquarie Investment Management Business Trust.
(b)
Address or principal business office or, if none, residence:
The principal business address of Macquarie Group Limited is Level 1, 1 Elizabeth Street, Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 610 Market Street, Philadelphia, PA 19106.
(c)
Citizenship:
Macquarie Group Limited - Sydney, New South Wales, Australia Corporation. Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust- incorporated or formed under the laws of the State of Delaware.
(d)
Title of class of securities:
Common Shares
(e)
CUSIP No.:
89422G107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See responses on the cover page hereto
(b)
Percent of class:
See responses on the cover page hereto
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See responses on the cover page hereto
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
See responses on the cover page hereto
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit A
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
